Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $28.00

Adaptive Biotechnologies (NASDAQ:ADPT) had its price objective lifted by TD Cowen from $25.00 to $28.00 in a research report released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other analysts also recently commented on the company. Guggenheim increased their price target on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. JPMorgan Chase & Co. reduced their price objective on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Morgan Stanley raised their target price on Adaptive Biotechnologies from $18.00 to $20.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Finally, BTIG Research lifted their target price on Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Adaptive Biotechnologies has an average rating of “Moderate Buy” and an average target price of $23.33.

Adaptive Biotechnologies Trading Down 6.7%

NASDAQ:ADPT opened at $22.57 on Thursday. The company has a debt-to-equity ratio of 2.22, a quick ratio of 3.22 and a current ratio of 4.79. The firm has a market cap of $3.61 billion, a price-to-earnings ratio of -55.05 and a beta of 2.07. Adaptive Biotechnologies has a 52 week low of $9.96 and a 52 week high of $24.57. The firm has a 50-day moving average price of $19.43 and a two-hundred day moving average price of $16.66.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its earnings results on Tuesday, July 28th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The business had revenue of $71.55 million during the quarter, compared to analysts’ expectations of $65.44 million. During the same quarter in the previous year, the firm earned ($0.17) EPS. Adaptive Biotechnologies’s quarterly revenue was up 21.5% on a year-over-year basis. On average, equities analysts expect that Adaptive Biotechnologies will post -0.43 earnings per share for the current fiscal year.

Insider Activity at Adaptive Biotechnologies

In related news, insider Sharon Benzeno sold 154,768 shares of Adaptive Biotechnologies stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $21.14, for a total value of $3,271,795.52. Following the sale, the insider owned 221,278 shares of the company’s stock, valued at approximately $4,677,816.92. The trade was a 41.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Francis Lo sold 44,838 shares of Adaptive Biotechnologies stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $22.59, for a total transaction of $1,012,890.42. Following the completion of the sale, the insider directly owned 230,713 shares in the company, valued at $5,211,806.67. This trade represents a 16.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,305,787 shares of company stock worth $27,828,563. 5.70% of the stock is currently owned by company insiders.

Institutional Trading of Adaptive Biotechnologies

Several hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC grew its stake in shares of Adaptive Biotechnologies by 45.8% during the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after acquiring an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after acquiring an additional 2,914 shares during the last quarter. Caxton Associates LLP bought a new stake in Adaptive Biotechnologies in the 1st quarter valued at about $93,000. New York State Common Retirement Fund raised its stake in Adaptive Biotechnologies by 39.2% in the 2nd quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock valued at $551,000 after acquiring an additional 13,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Adaptive Biotechnologies by 728.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after purchasing an additional 333,379 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive raised its 2026 MRD revenue outlook to $268 million-$278 million and outlined plans to separate the MRD business. Management and analysts view the transaction as a potential way to create a focused, higher-growth “pure-play” company and unlock shareholder value. Adaptive outlines MRD separation plan while raising 2026 MRD revenue guidance
• Positive Sentiment: Second-quarter revenue was approximately $71.6 million, above the roughly $65.4 million consensus estimate and up 21.5% year over year. Zacks also reported an adjusted loss of $0.10 per share, narrower than the expected $0.13 loss and the $0.17 loss in the prior-year quarter. Adaptive Biotechnologies Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Analysts raised their targets after the results: TD Cowen increased its target to $28 and maintained a Buy rating, while BTIG lifted its target to $25 and also retained a Buy rating. Analyst price-target coverage
• Neutral Sentiment: Zacks noted that ADPT’s 52-week-high performance reflects improving fundamentals, but investors must assess whether revenue growth, margins and the MRD separation can support additional appreciation. Adaptive Biotechnologies Hit a 52 Week High
• Negative Sentiment: Morgan Stanley raised its target only to $22 and kept an Equal Weight rating, implying limited upside at recent trading levels. The company remains unprofitable, and reported GAAP results included a larger-than-consensus quarterly loss, highlighting ongoing execution and profitability risks.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.